4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
HUTCHMED (China) Limited (0013) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Hong Kong, Hong Kong with about 1,790 employees. Its market capitalization is roughly $17 billion. In the fiscal year ended 2025-12-31, 0013 reported $548M in revenue and $457M in net income.
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $548M | $630M | $838M | $426M | — |
| Gross Profit | $212M | $281M | $454M | $115M | — |
| Operating Income (EBIT) | ($36M) | ($41M) | $22M | ($406M) | — |
| Net Income | $457M | $38M | $101M | ($361M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $1.8B | $1.3B | $1.3B | $1.0B | — |
| Total Liabilities | $502M | $502M | $536M | $393M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 0013 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms